Equities

Kangmei Pharmaceutical Co Ltd

600518:SHH

Kangmei Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)1.83
  • Today's Change0.01 / 0.55%
  • Shares traded37.19m
  • 1 Year change-16.44%
  • Beta1.0419
Data delayed at least 15 minutes, as of Jun 14 2024 07:35 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Kangmei Pharmaceutical Co., Ltd is a China-based company, principally engaged in the manufacture and sales of pharmaceutical products. The Company's principal products are Chinese medicines, including American ginseng, notoginseng powder, salvia powder, radix codonopsis pilosulae, maltiflower knotweed, angelica and lonicera flower, among others. The Company is also engaged in the trading of Chinese herbal medicines, medical equipment and healthcare products related businesses. It also engages in the provision of real estate leasing and distribution services, among others. The Company mainly conducts its businesses within domestic markets.

  • Revenue in CNY (TTM)4.93bn
  • Net income in CNY160.40m
  • Incorporated1997
  • Employees4.41k
  • Location
    Kangmei Pharmaceutical Co LtdTaike Road, Xiameilin, Futian DistrictSHENZHEN 518000ChinaCHN
  • Phone+86 75 533187777
  • Fax+86 75 586275777
  • Websitehttp://www.kangmei.com.cn/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Chongqing Taiji Industry Group Co Ltd15.40bn834.00m21.07bn12.59k25.265.44--1.371.501.5027.666.951.033.155.841,223,535.005.770.781417.832.3546.1444.035.620.84980.53156.120.539325.7610.587.88131.9963.553.8624.57
China Resources Dubl-Crne Phrmctl Co Ltd10.32bn1.38bn22.20bn12.27k15.911.90--2.151.341.3410.0711.240.67812.855.82841,054.608.878.5811.6711.2154.2558.1913.0811.982.15--0.024935.916.204.4412.966.6021.46-1.63
Xiamen Amoytop Biotech Co Ltd2.23bn600.08m22.33bn1.96k37.2011.13--10.031.481.485.474.931.040.85416.701,135,877.0028.0917.9632.7221.0293.1790.4826.9519.173.22--0.003726.9537.5536.1993.52103.2881.61--
Joincare Pharmaceutical Group Ind. Co.16.43bn1.42bn23.07bn14.37k16.101.62--1.400.76760.76768.867.630.45222.365.571,143,551.007.988.4616.5118.8461.2362.7217.6417.002.11--0.224728.86-2.908.24-3.9915.5811.532.38
Kangmei Pharmaceutical Co Ltd4.93bn160.40m25.65bn4.41k159.073.62--5.200.01160.01160.35770.51170.341.402.431,118,464.001.12-17.601.69-32.2422.71-72.783.28-101.190.8746--0.0465--16.60-22.17103.81-22.83-53.51--
Shanghai Junshi Biosciences Co Ltd1.63bn-2.02bn25.70bn2.57k--4.34--15.78-2.06-2.061.666.970.13481.054.11634,034.10-18.18-18.87-23.17-23.1164.0569.13-134.86-88.411.91-215.800.3018--3.38248.394.38--8.36--
Zhejiang Huahai Pharmaceutical Co., Ltd.8.75bn928.37m25.72bn8.22k27.153.01--2.940.63910.63916.025.760.45111.083.461,064,162.004.765.676.908.0759.4460.5210.5511.610.84515.480.504733.550.519910.28-28.8850.517.21--
Bluestar Adisseo Co13.53bn327.58m26.52bn2.73k80.971.76--1.960.12220.12225.045.630.62864.677.334,947,799.001.525.281.856.9423.8130.312.428.761.044.300.132521.81-9.262.92-95.82-43.752.74-19.09
Autobio Diagnostics Co Ltd4.50bn1.30bn28.15bn5.54k21.473.18--6.262.242.247.7415.110.40662.084.27811,768.3011.8112.5914.5015.7964.7661.6229.0426.962.81--0.103546.400.045718.154.2816.7017.0311.32
Shanghai Allist Pharmaceuticals Co Ltd2.48bn915.35m28.21bn1.04k30.816.53--11.352.032.035.529.600.60913.1610.512,379,802.0022.440.640524.190.693394.4896.4236.842.548.22--0.0004211.88155.14237.34393.54--13.53--
Gan & Lee Pharmaceuticals2.61bn386.85m29.06bn4.48k71.982.63--11.130.67160.67164.5218.380.2340.892610.97582,412.303.478.303.718.8372.2985.3914.8326.447.74--0.000613.6552.311.78177.37-18.301.50--
Data as of Jun 14 2024. Currency figures normalised to Kangmei Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

4.13%Per cent of shares held by top holders
HolderShares% Held
Minmetals International Trust Co.,Ltd.as of 30 Jun 2023231.90m1.70%
Guangdong Finance Trust Co., Ltd.as of 30 Jun 2023181.82m1.34%
Chang'An International Trust Co., Ltd.as of 30 Jun 2023148.00m1.09%
Mellon Investments Corp.as of 09 May 2024233.93k0.00%
China Life AMP Asset Management Co., Ltd.as of 31 Dec 2017151.66k0.00%
UBS Asset Management Switzerland AGas of 29 Feb 202432.92k0.00%
F�rsta AP-fondenas of 31 Dec 202317.04k0.00%
UBS Asset Management (UK) Ltd.as of 29 Feb 20247.78k0.00%
DWS Investments (UK) Ltd.as of 09 May 20247.48k0.00%
Danske Bank A/S (Investment Management)as of 30 Apr 20247.35k0.00%
More ▼
Data from 30 Jun 2023 - 31 May 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.